US FDA Issues Import Alert Against Dabur India’s Silvassa Plant: What the Bird Droppings Finding Really Means
A live bird was found in a raw material warehouse. Thirty feet from packaging materials.
That single detail, buried in a US Food and Drug Administration inspection report, tells you more about why the US FDA import alert on Dabur India's Silvassa plant happened than any corporate filing ever will.
The US Food and Drug Administration has issued an import alert for drugs manufactured at Dabur India's factory in Dadra and Nagar Haveli following an inspection. The action was taken after the FDA inspected the factory and flagged data integrity and maintenance lapses.
This is not a minor paperwork problem. This is a formal regulatory action with real consequences for what Dabur can ship to the United States.
What the FDA Found at the Silvassa Plant
Last month, Reuters reported citing the inspection report that the regulator found critical manufacturing records were falsified to conceal that equipment meant to make certain products had been used for multiple other products. A live bird and bird droppings were found in the raw material warehouse, about 30 feet from packaging materials.
Read More: Oman in the Crossfire: Why the World's Most Neutral Nation Is Now Under Enormous Pressure
Two separate categories of failure. The first is a data integrity violation , falsified records are among the most serious findings the FDA can make, because they suggest the problem is not accidental but systematic. If a company is altering manufacturing records to hide cross-contamination of equipment, that raises questions about every product that came out of that facility.
The second is a hygiene failure , a live bird near packaging materials in a pharmaceutical warehouse is a basic contamination risk that no amount of process documentation can excuse.
The alert pertains to drugs manufactured at the company's plant located in Silvassa, Dadra and Nagar Haveli, and follows an inspection that identified certain deficiencies related to data integrity and maintenance lapses at the facility.
What Import Alert IA 66-40 Actually Does
A product placed on an FDA import alert can be detained without physical examination unless the importer demonstrates that it has addressed the violations cited in the alert.
This is the practical consequence. Products from the affected section of the Silvassa plant cannot enter the United States unless Dabur can prove the specific problems have been fixed. US Customs does not need to open the box to detain the shipment. The alert itself is sufficient grounds for detention.
Dabur India Ltd. announced that the US FDA has issued Import Alert IA 66-40, effective June 10, 2026.
Dabur's Response: Limited Revenue Impact, Corrective Action Underway
Dabur moved quickly to contain the reputational fallout. The action does not have any financial or operational impact, and domestic products manufactured at the Silvassa plant are not covered by this alert and remain unaffected. The Silvassa plant continues to be operational.
Dabur clarified that only a small section making private-label products, which barely impact its revenue, is affected. They have started fixing the problems identified by the FDA, and tests show no quality concerns so far. To keep US customers supplied, they are switching up sourcing strategies.
Management has moved quickly to state that the financial repercussions will be negligible on the consolidated books. Revenue impact is estimated at less than 1% of consolidated turnover.
The less-than-1% figure is a reassurance for investors, and it is probably accurate. But it does not diminish the seriousness of the underlying compliance failures. Data falsification and unsanitary storage conditions are not issues that resolve with a corrective action plan submitted to a regulator. They reflect something structural that needs examination.
Why This Matters Beyond Dabur's Balance Sheet
Dabur is one of India's oldest and largest consumer goods companies, describing itself as one of the world's largest suppliers of Ayurvedic products with a legacy of over 140 years. It sells a range of over-the-counter and consumer health products in the United States, including cough and cold rubs, antifungal creams, pain relief gels and oral care products.
The US FDA Dabur import alert is another chapter in a long story of Indian pharmaceutical and consumer health manufacturers facing serious scrutiny from American regulators. The FDA's standards for good manufacturing practices (GMP) apply equally whether the product is a blockbuster drug or an Ayurvedic topical cream. Data integrity is non-negotiable. Hygiene in raw material storage is non-negotiable.
The corrective and preventive action plans Dabur is now submitting to the FDA will determine when and whether the import alert is lifted. That process typically takes months, sometimes longer.
Read More: Xi Jinping Visits North Korea After Seven Years: What Kim Jong Un Told Him Before He Even Landed
Disclaimer: This article is based on information available across the web. Parchar Manch does not take responsibility for its complete accuracy, as the content could not be fully verified.
FAQs
What is the US FDA import alert issued against Dabur India?
The US FDA issued Import Alert IA 66-40, effective June 10, 2026, concerning drugs manufactured at Dabur's Silvassa plant in Dadra and Nagar Haveli, following an inspection that found data integrity and maintenance deficiencies.
What violations did the FDA find at the Dabur Silvassa plant?
The FDA found that critical manufacturing records were falsified to conceal cross-use of equipment, and that a live bird and bird droppings were found in the raw material warehouse about 30 feet from packaging materials.
Does the Dabur FDA import alert affect products sold in India?
No. Domestic products manufactured at the Silvassa plant are not covered by this alert and remain unaffected.
What happens to Dabur's US shipments under an import alert?
Products placed on an FDA import alert can be detained without physical examination unless the importer demonstrates that the violations cited in the alert have been addressed.
How significant is the financial impact on Dabur?
Management estimates the revenue impact at less than 1% of consolidated turnover, calling it negligible on the consolidated books.